Senior Finance Business Partner (Drug Design and Development), London, UK

The role

You will serve as the dedicated finance partner to the drug discovery organisation. You will manage financial activities for drug development work from discovery to preclinical testing.

What you will do

• Serve as the primary finance partner for the Drug Design and Development team
• Provide strategic thought partnership to support delivery of portfolio objectives
• Lead end-to-end budgeting, forecasting, and resource planning
• Provide financial decision support for the Portfolio Steering Team
• Build project-level NPV and risk-adjusted valuation models for pipeline assets
• Partner with Business Development to model economics for partnerships, licensing deals, and collaborations
• Partner with External Research team and Procurement during RFP processes to evaluate and negotiate vendor budgets
• Deliver regular variance analysis
• Enhance financial reporting and workflows
• Oversee accruals processes

Required qualifications

• Direct experience managing R&D / drug development finance and FP&A/partnering within biotech, pharma, or life sciences
• Deep experience building and maintaining robust financial models for portfolio prioritisation and project NPV
• Degree in Finance, Accounting, Economics or other quantitative field
• Clear executive-level communicator for both technical and non-technical audiences
• Strong attention to detail and ability to manage competing priorities in a fast-paced environment
• Proven track record in business partnering, influencing senior leadership, and excellence in stakeholder management
• Experience in utilizing LLMs and other AI to drive efficiency

Nice to have

• Professional accounting qualification (e.g., ACA, ACCA, CIMA, CPA, or equivalent)
• Life sciences background/experience highly desirable
• Experience using Google Workspace (Sheets, Slides etc)
• Experience implementing or managing financial systems (e.g. ERP, procurement)

About the company

Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. The company uses AI models to accelerate scientific discovery and design novel molecules.